Prime Medicine (PRME) Reiterated at Market Outperform by Citizens

October 6, 2026 5:35 AM

Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $7.00 price target on Prime Medicine (NASDAQ: PRME).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found